Loading stock data…
Ironwood Pharmaceuticals, Inc. (IRWD)
$4.17-0.09 (-2.11%)
Market ClosedLast close Sep 8
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ironwood Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.17 with a market capitalization of $533M. Wall Street consensus targets $6.10 (4 analysts), implying a +46.3% move over the next 12 months. The stock is currently 28% below its 52-week high of $5.78, remaining 5.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +46.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $113.04M↑ | $106.51M↑ | $47.71M↓ | $122.06M↑ | $85.24M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $79.31M↑ | $72.53M↑ | $6.55M↓ | $77.68M↑ | $45.07M |
| Net Income | $51.29M↑ | $40.77M↑ | -$2.28M↓ | $40.08M↑ | $23.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase typ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$533.35M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.23
Beta
Defensive asset. Lower volatility than the S&P 500.
0.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.05%
Volume
Today's trading volume
2.27M
Recent News
Ironwood (IRWD) Q2 2026 Earnings Call Transcript
LINZESS sales surged 14% as company raised full-year guidance.
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Ironwood Pharmaceuticals, Inc.'s Q2 2026 earnings call
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?
Ironwood Pharmaceuticals reported past second-quarter 2026 results showing sales of US$113.04 million versus US$85.24 million a year earlier, with net income rising to US$51.29 million from US$23.6 million and earnings per share from continuing operations doubling to US$0.31 basic and US$0.31 diluted. For the first half of 2026, the company grew sales to US$219.55 million from US$126.38 million and shifted from a loss to a US$92.06 million profit, prompting management to raise full-year 2026...
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ...
Ironwood Pharmaceuticals Inc (IRWD) raises full-year 2026 outlook on robust LINZESS performance and promising apraglutide data.
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, prompting the company to raise its full-year 2026 financial outlook. Chief Execu